PreludeDx Welcomes MiMi Reyes as Senior VP to Enhance Operational Strategies

PreludeDx's New Leadership Appointment

PreludeDx, a frontrunner in precision diagnostics for early-stage breast cancer, has recently appointed MiMi Reyes as their new Senior Vice President of Operations. This strategic move comes as the company aims to enhance its operational capabilities and meet the increasing demand for its diagnostic technologies.

About MiMi Reyes

With over 25 years of substantial experience in the diagnostics and medical device industries, Reyes brings a wealth of knowledge to her new role. Her impressive background includes leadership positions in both national and international arenas, allowing her to effectively manage laboratories compliant with CAP, CLIA, FDA, ISO 9001, and ISO 13485 standards.

Reyes expressed her enthusiasm about joining PreludeDx, stating, "I'm excited to join PreludeDx at an important time for the company. PreludeDx has built a strong foundation in precision diagnostics, and I look forward to partnering across teams to further strengthen operations, innovation, and ensure the delivery of high-quality testing that positively impacts patients."

Experience and Achievements

Before joining PreludeDx, Reyes was part of the Executive Management team at MDxHealth, where she led Global Operations and developed innovative diagnostic testing programs for several cancers, solidifying her reputation as a results-driven executive. In her early career, she played a pivotal role at Agendia, helping to launch MammaPrint, a test for early-stage breast cancer. Furthermore, Reyes has held significant positions at CombiMatrix and US LABS, underscoring her extensive expertise in the field of diagnostics.

Dan Forche, President and CEO of PreludeDx, highlighted Reyes' unmatched operational leadership and her deep understanding of the regulated diagnostics sector. He noted, "MiMi's operational leadership, deep understanding of regulated diagnostics, and proven ability to build and scale high-quality laboratory operations make her an exceptional addition to PreludeDx. Her experience will be instrumental as we strengthen our operations to support higher patient demand and the new launch of our AidaBreast invasive breast cancer test."

The Future of PreludeDx

As PreludeDx gears up for the launch of its AidaBreast test, which focuses on invasive breast cancer diagnostics, Reyes’ role will be crucial in enhancing laboratory operations to meet growing patient needs. This initiative reflects the company’s commitment to providing innovative diagnostic solutions that are tailored for optimal patient outcomes.

Educational Background

MiMi Reyes holds a Bachelor of Science degree in Biology from the University of California, Irvine, and an Executive Healthcare MBA from the same institution's Paul Merage School of Business. This strong educational foundation, coupled with her extensive industry experience, positions her perfectly to lead PreludeDx into its next phase of growth.

PreludeDx's Commitment

Founded in 2009 with pioneering technology from the University of California San Francisco, PreludeDx is dedicated to improving breast cancer diagnostics and personalizing patient care. The company’s mission revolves around developing cutting-edge tools that enhance treatment decisions while aiming to minimize healthcare costs.

In conclusion, MiMi Reyes' appointment as Senior VP marks an exciting new chapter for PreludeDx, as the company strives to adapt and innovate within the rapidly evolving healthcare landscape. With her leadership, PreludeDx is well-positioned to continue making significant strides in the realm of precision diagnostics for breast cancer.